Important Information Regarding Vyzulta

Posted in Latest News on March 16, 2018.

During the March 9, 2018 Board of Optometry meeting, the board approved for addition to Rule 64B13-18.002 Formulary of Topical Ocular Pharmaceutical Agents, Vyzulta (latanoprostene bunod ophthalmic solution) 0.024%.

Important note, Vyzulta, at this time, cannot be prescribed by certified Optometrists in Florida until the rule has been approved. Once the rule has gone through the approval process, notice will be provided on this site, and at that time Vyzulta may be prescribed by certified optometrists.

 



More Latest News

NTSB Study on Drug Use Trends in Aviation
March 8, 2021

National Transportation Safety Board issues recommendations to states on prescribing controlled substances for pain and the dangers of operating a vehicle in any mode of transportation Continue reading


Second Quarter Performance Report
March 4, 2021

Released for Fiscal Year
2020-2021 Continue reading